{"commentary":{"count":14,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":7,"podcast":4,"x_thread":3},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03235245\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"EBIN","nct_id":"NCT03235245","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=ebin-nct03235245. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"EBIN","arms":[{"description":"nivolumab 3 mg/kg q3w + ipilimumab 1 mg/kg q3w for 4 injections followed by nivolumab 480 mg IV q4w until completion of 2 years total treatment or progression. Then treatment will be left at the investigator choice and continued until the 2nd progression.","label":"ARM A: Nivolumab + Ipilimumab","type":"ACTIVE_COMPARATOR"},{"description":"encorafenib 450 mg QD + binimetinib 45 mg BID orally for 12 weeks followed, after a week of pause, by nivolumab 3 mg/kg q3w + ipilimumab 1 mg/kg q3w for 4 injections, followed by nivolumab 480 mg IV q4w until completion of 2 years total treatment or progression. Then patients will be rechallenged with encorafenib 450 mg QD + binimetinib 45 mg BID orally continuously until the 2nd progression.","label":"ARM B: Encorafenib + Binimetinib + Nivolumab + Ipilimumab","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2027-01","type":"ESTIMATED"},"conditions":["Unresectable Stage III Melanoma","Stage IV Melanoma"],"enrollment":{"count":271,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Nivolumab + Ipilimumab","type":"DRUG"},{"name":"Encorafenib + Binimetinib","type":"DRUG"}],"last_update":"2025-08-01","lead_sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","official_title":"Combination of Targeted Therapy (Encorafenib and Binimetinib) Followed by Combination of Immunotherapy (Ipilimumab and Nivolumab) vs Immediate Combination of Immunotherapy in Patients With Unresectable or Metastatic Melanoma With BRAF V600 Mutation : an EORTC Randomized Phase II Study (EBIN)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2023-10-24","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression Free Survival (PFS)","timeFrame":"4.1 years from first patient in"}],"references":[{"citation":"Robert C, Kicinski M, Dutriaux C, Routier E, Govaerts AS, Buhrer E, Neidhardt EM, Durando X, Baroudjian B, Saiag P, Gaudy-Marqueste C, Ascierto PA, Arance A, Russillo M, Perrot JL, Mortier L, Aubin F, Dalle S, Grange F, Munoz-Couselo E, Mary-Prey S, Amini-Adle M, Mansard S, Lebbe C, Funck-Brentano E, Monestier S, Eggermont AMM, Oppong F, Wijnen L, Schilling B, MandalA M, Lorigan P, van Akkooi ACJ. Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced melanoma with BRAFV600E or BRAFV600K mutations (EBIN): an international, open-label, randomised, controlled, phase 2 study. Lancet Oncol. 2025 Jun;26(6):781-794. doi: 10.1016/S1470-2045(25)00133-0.","pmid":"40449497","type":"DERIVED"}],"start_date":{"date":"2018-10-30","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib","url":"https://clinicaltrials.gov/study/NCT03235245"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/ebin-nct03235245"}